Oric Pharmaceuticals Q3 2024 Earnings Report

Oric Pharmaceuticals EPS Results

• Actual EPS: -$0.49
• Consensus EPS: -$0.48
• Beat/Miss: Missed by -$0.01
• One Year Ago EPS: N/A

Oric Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Oric Pharmaceuticals Announcement Details

• Quarter: Q3 2024
• Date: 11/12/2024
• Time: After Market Closes
• Conference Call Date: Tuesday, November 12, 2024
• Conference Call Time: 4:00PM ET

Oric Pharmaceuticals (NASDAQ:ORIC) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents. In addition, ORIC-944, a potent inhibitor of discoidin domain receptors 1 and 2 (DDR1/2), is in late preclinical development for modulation of fibrotic tumor stroma and metastatic disease control. Oric applies translational biology and biomarker-driven strategies to guide patient selection and optimize therapeutic indices across its programs.

Founded in 2016 by a team of oncology R&D veterans, Oric Pharmaceuticals completed its initial public offering on the Nasdaq Global Market in March 2021 under the ticker symbol ORIC. The company has established collaborative relationships with leading academic institutions and clinical research organizations across North America and Europe to support its global clinical development plans. Its senior management team is led by President and Chief Executive Officer Johanna Mercier, Ph.D., who brings extensive experience in small molecule drug discovery and development from prior roles at major pharmaceutical companies.

Oric leverages a proprietary target discovery platform that integrates genomic, proteomic and functional screening data to uncover resistance pathways and potential combination strategies. By incorporating biomarker analyses early in development, the company aims to accelerate timelines and deliver therapies with differentiated mechanisms of action. Multiple programs are advancing through IND-enabling studies, with key clinical milestones anticipated over the coming 12 months.